Company logo

SUNPHARMA - Sun Pharmaceutical Industries Limited

NSE -> Healthcare -> Drug Manufacturers—Specialty & Generic
Mumbai, India
Type: Equity

SUNPHARMA price evolution
SUNPHARMA
(in millions $) 29 Sep 2022 29 Jun 2022 30 Mar 2022 30 Dec 2021
Current assets
Cash $53610.8 $50333.5
Short term investments $84739.3 $76339.4
Net receivables $123856.7 $107628.6
Inventory $98747.8 $89968.1
Total current assets $390028.8 $350149.8
Long term investments $47830.2 $52146.5
Property, plant & equipment $113370.3 $111688.9
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $744554.9 $697998.7
Current liabilities
Accounts payable $51087.6 $44793.4
Deferred revenue
Short long term debt $38069.1 $7007.7
Total current liabilities $167014.9 $172005.5
Long term debt $2299.2
Total noncurrent liabilities
Total debt
Total liabilities $180913.8 $187337.6
Shareholders' equity
Retained earnings $412363
Other shareholder equity $528780 $477712.9
Total shareholder equity $531179.3 $480112.2 $480112.2 $495362.5
(in millions $) 30 Mar 2022 30 Mar 2021 30 Mar 2020 30 Mar 2019
Current assets
Cash $50333.5 $64455.1 $56766.1 $70623
Short term investments $76339.4 $40059.9 $30740.1 $27214.2
Net receivables $107628.6 $91174.1 $105105.8 $100629.9
Inventory $89968.1 $89970.2 $78749.9 $78859.8
Total current assets $350149.8 $304420.8 $316541.6 $310691.9
Long term investments $52146.5 $65781.7 $52457.5 $39518.1
Property, plant & equipment $111688.9 $111715.1 $112263.4 $109382.1
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $697998.7 $676667.3 $682524.6 $646938.1
Current liabilities
Accounts payable $44793.4 $39736.6 $40937.3 $41478.7
Deferred revenue
Short long term debt $2322.5 $4238.8 $6438.6 $5860.9
Total current liabilities $172005.5 $161456.3 $157064.3 $173396.2
Long term debt $2299.2 $8981.3 $17776.1 $14228.7
Total noncurrent liabilities
Total debt
Total liabilities $187337.6 $181869 $191277.7 $199712.1
Shareholders' equity
Retained earnings $412363 $401887.4 $389052 $369130.4
Other shareholder equity $477712.9 $462228.5 $49319.1 $30628
Total shareholder equity $480112.2 $464627.8 $452644.5 $414090.6
(in millions $) 29 Sep 2022 29 Jun 2022 30 Mar 2022 30 Dec 2021
Revenue
Total revenue $109522.8 $107617.6 $94467.6 $98630.6
Cost of revenue $27080.7 $29002 $25396.3 $26406.2
Gross Profit $82442.1 $78615.6 $69071.3 $72224.4
Operating activities
Research & development
Selling, general & administrative $20045.6 $20748.5 $18849.1 $18509.1
Total operating expenses $83642.1 $86110.4 $78238.8 $77998.2
Operating income $25880.7 $21507.2 $16228.8 $20632.4
Income from continuing operations
EBIT $25880.7 $21507.2 $16228.8 $20632.4
Income tax expense $1522.6 $1889.9 $1467.6 $3353.9
Interest expense -$193.9 -$136.9 -$373.4 -$189.7
Net income
Net income $22622.2 $20608.8 -$22772.5 $20588
Income (for common shares) $22622.2 $20608.8 -$22772.5 $20588
(in millions $) 30 Mar 2022 30 Mar 2021 30 Mar 2020 30 Mar 2019
Revenue
Total revenue $386544.9 $334981.4 $328375 $290659.1
Cost of revenue $103515.4 $86900.8 $96796.3 $83838.9
Gross Profit $283029.5 $248080.6 $231578.7 $206820.2
Operating activities
Research & development
Selling, general & administrative $73008.3 $68622.3 $63985.9 $60998.5
Total operating expenses $305544.7 $271103.7 $278657.3 $243286
Operating income $81000.2 $63877.7 $49717.7 $47373.1
Income from continuing operations
EBIT $81000.2 $63877.7 $49717.7 $47373.1
Income tax expense $10755 $9242 $8228 $6008.8
Interest expense -$1273.5 -$1414.3 -$3027.3 -$5505.8
Net income
Net income $32727.3 $29038.2 $37649.3 $26654.2
Income (for common shares) $32727.3 $29038.2 $37649.3 $26654.2
(in millions $) 29 Sep 2022 29 Jun 2022 30 Mar 2022 30 Dec 2021
Net income $22622.2 $20608.8 -$22772.5 $20588
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing
Effect of exchange rate
Change in cash and equivalents
(in millions $) 30 Mar 2022 30 Mar 2021 30 Mar 2020 30 Mar 2019
Net income $32727.3 $29038.2 $37649.3 $26654.2
Operating activities
Depreciation $21437.4 $20799.5 $20084.8 $17229.3
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations $89845.4 $61703.7 $65547.7 $21964.5
Investing activities
Capital expenditures -$14950.4 -$11701.3 -$15420 -$32128.2
Investments -$37910.7 $13732.7 -$17019.2 $17524.4
Total cash flows from investing -$57247.4 $5362.2 -$25888.4 -$6812.5
Financing activities
Dividends paid -$21589.2 -$15594.7 -$13791.9 -$4801.8
Sale and purchase of stock
Net borrowings -$27653.6 -$44896.4 -$31229.9 -$2372
Total cash flows from financing -$51934.6 -$59804.8 -$57151.4 -$27305.2
Effect of exchange rate $1274.3 -$1296.9 $3635.2 $3256.5
Change in cash and equivalents -$17647.8 $5964.2 -$13856.9 -$8441.5
Fundamentals
Market cap N/A
Enterprise value N/A
Shares outstanding N/A
Revenue $410.24B
EBITDA N/A
EBIT $84.25B
Net Income $41.05B
Revenue Q/Q 13.78%
Revenue Y/Y 11.77%
P/E ratio N/A
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio N/A
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS N/A
ROA N/A
ROE 8.26%
Debt/Equity 0.39
Net debt/EBITDA N/A
Current ratio 2.34
Quick ratio 1.74